Rev/Dex

Multiple Myeloma

Rev/Dex low dose

Lenalidomide (Revlimid) 25 mg po qd d1-21
Dexamethasone (Decadron) 40 mg po d1, 8, 15, 22
Q4w

References

Rajkumar SV et al. Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. 2007 ASCO annual meeting. LBA8025.

Rev/Dex high dose

Lenalidomide (Revlimid) 25 mg po qd d1-21
Dexamethasone (Decadron) 40 mg po qd d1-4, 9-12, 17-20
Q4w

References

Rajkumar SV et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005; 106:4050 (link to the article).

Rev +/- Dex

Lenalidomide (Revlimid) 30 mg po qd d1-21 q4w
Dexamethasone (Decadron) 40 mg po qd d1-4 q2w

References

Richardson PG et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006; 108: 3458